Drug Profile
B 001
Alternative Names: B001; B001-A; B001-CLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Shanghai Pharmaceuticals Holding
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neuromyelitis optica
- Preclinical Multiple sclerosis
- No development reported Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia in China (IV, Injection)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in China (IV, Injection)
- 27 Sep 2022 Shanghai Pharmaceuticals plans a phase I trial for Membranous-glomerulonephritis (SC)